Phase II study of ONYX-015 in patients with hepatobiliary tumors with p53 correlative studies

被引：0
|
作者：
Wadler, S
Makower, D
Yu, B
Tan, JY
Rozenblit, A
Kaufman, H
Edelman, M
Lane, M
Zwiebel, J
Horwitz, M
机构：
[1] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA
[3] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY USA
[4] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA
[5] Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA
[7] Albert Einstein Coll Med, Dept Microbiol Immunol, Bronx, NY 10467 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [1] Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies
    Makower, D
    Rozenblit, A
    Kaufman, H
    Edelman, M
    Lane, ME
    Zwiebel, J
    Haynes, H
    Wadler, S
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 693 - 702
  • [2] Efficacy of p53-directed ONYX-015 therapy in hepatobiliary tumors.
    Makower, D
    Rozenblit, A
    Edelman, M
    Augenlicht, L
    Kaufman, H
    Haynes, H
    Zwiebel, J
    Wadler, S
    CLINICAL CANCER RESEARCH, 1999, 5 : 3772S - 3772S
  • [3] Phase IIB trial of ONYX-015 therapy in hepatobiliary tumors
    Makower, D
    Rozenblit, A
    Edelman, M
    Augenlicht, L
    Kaufman, H
    Haynes, H
    Zwiebel, J
    Wadler, S
    CANCER GENE THERAPY, 1999, 6 (06) : S16 - S16
  • [4] Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015
    McCormick, F
    SEMINARS IN CANCER BIOLOGY, 2000, 10 (06) : 453 - 459
  • [5] ONYX-015 phase II clinical trial results
    Senior, Kathryn
    LANCET ONCOLOGY, 2001, 2 (01): : 3 - 3
  • [6] In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
    Rogulski, KR
    Freytag, SO
    Zhang, K
    Gilbert, JD
    Paielli, DL
    Kim, JH
    Heise, CC
    Kirn, DH
    CANCER RESEARCH, 2000, 60 (05) : 1193 - 1196
  • [7] Cancer therapy based on p53: The adenovirus mutant dI1520 (ONYX-015)
    Korn, WM
    CANCER GENE THERAPY, 2000, 7 (08) : 1206 - 1206
  • [8] Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
    Rothmann, T
    Hengstermann, A
    Whitaker, NJ
    Scheffner, M
    zur Hausen, H
    JOURNAL OF VIROLOGY, 1998, 72 (12) : 9470 - 9478
  • [9] Onyx reports encouraging phase II results of Onyx-015 in head and neck cancer
    不详
    DRUG NEWS & PERSPECTIVES, 1998, 11 (09) : 595 - 595
  • [10] Phase I/II trial of ONYX-015 in combination with chemotherapy in patients with advanced sarcomas
    Galanis, E
    Okuno, S
    Lewis, B
    Oliveira, A
    Nascimento, A
    Sloan, J
    Edmonson, J
    Randlev, B
    Uprichard, M
    Rubin, J
    GENE THERAPY, 2001, 8 : S8 - S8
12345